N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
出版年份 2013 全文链接
标题
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
作者
关键词
AD 198, Non-Hodgkin lymphoma, Multiple myeloma, TRAF3, c-Myc
出版物
BMC CANCER
Volume 13, Issue 1, Pages -
出版商
Springer Nature
发表日期
2013-10-17
DOI
10.1186/1471-2407-13-481
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice
- (2011) C R Moore et al. LEUKEMIA
- Two Faces of Protein Kinase Cδ: The Contrasting Roles of PKCδ in Cell Survival and Cell Death
- (2011) Alakananda Basu et al. TheScientificWorldJOURNAL
- Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005)
- (2010) Peter Hampson et al. APOPTOSIS
- The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma
- (2010) Sonali M. Smith et al. BLOOD CELLS MOLECULES AND DISEASES
- Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs
- (2010) María Ines Díaz Bessone et al. BREAST CANCER RESEARCH AND TREATMENT
- TNF Receptor-Associated Factor 3 Is Required for T Cell-Mediated Immunity and TCR/CD28 Signaling
- (2010) P. Xie et al. JOURNAL OF IMMUNOLOGY
- Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)
- (2010) C. Cai et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- AP-1 Regulates Cyclin D1 and c-MYC Transcription in an AKT-Dependent Manner in Response to mTOR Inhibition: Role of AIP4/Itch-Mediated JUNB Degradation
- (2010) R. Vartanian et al. MOLECULAR CANCER RESEARCH
- The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity
- (2010) Elisabeth Ersvaer et al. Toxins
- The protein kinase C agonist PEP005 increases NF-κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells
- (2009) Astrid Marta Olsnes et al. BRITISH JOURNAL OF HAEMATOLOGY
- Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells
- (2009) A. Ghoul et al. CANCER RESEARCH
- Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor- B Signaling Pathways in Waldenstrom's Macroglobulinemia
- (2009) E. Braggio et al. CANCER RESEARCH
- Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)
- (2009) I Nagel et al. LEUKEMIA
- Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
- (2008) K A Benhadji et al. BRITISH JOURNAL OF CANCER
- The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner
- (2008) Peter Hampson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Roles of TRAF molecules in B lymphocyte function
- (2008) Ping Xie et al. CYTOKINE & GROWTH FACTOR REVIEWS
- TRAF2 and TRAF3 Signal Adapters Act Cooperatively to Control the Maturation and Survival Signals Delivered to B Cells by the BAFF Receptor
- (2008) Sandra Gardam et al. IMMUNITY
- MyD88 Intrinsically Regulates CD4 T-Cell Responses
- (2008) S. Zhou et al. JOURNAL OF VIROLOGY
- Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
- (2008) M. Serova et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started